Patents Assigned to MEREO BIOPHARMA 5, INC.
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20230279101
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 7, 2023
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 11512128
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 29, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20220340653
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 9, 2021
    Publication date: October 27, 2022
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR, Austin L. Gurney, Ming-Hong Xie
  • Methods and compositions for treatment of cancer
    Patent number: 11339213
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly colorectal, ovarian (e.g., platinum-resistant ovarian), pancreatic, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., leucovorin, 5-fluorouracil, and irinotecan; paclitaxel; gemcitabine and ABRAXANE® (albumin-bound paclitaxel for injectable suspension); and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a colorectal, ovarian, pancreatic, or endometrial tumor.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 24, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar, Robert Joseph Stagg
  • Methods for treatment of cancer comprising TIGIT-binding agents
    Patent number: 11230596
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 25, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar
  • Methods for treatment of cancer comprising TIGIT-binding agents
    Patent number: 11136384
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 5, 2021
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20210101971
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR